Amgen (NASDAQ:AMGN) Stock Sale Disclosed by Sen. Sheldon Whitehouse

Senator Sheldon Whitehouse (Democratic-Rhode Island) recently sold their entire stake in Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on November 2nd, the Senator disclosed that they had sold between $15,001 and $50,000 in Amgen stock on October 15th.

Senator Sheldon Whitehouse also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 10/15/2026.
• Sold $1,001 – $15,000 in shares of Analog Devices (NASDAQ:ADI) on 9/4/2026.
• Sold $1,001 – $15,000 in shares of Visa (NYSE:V) on 9/4/2026.
• Sold $15,001 – $50,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 9/4/2026.
• Sold $15,001 – $50,000 in shares of NVIDIA (NASDAQ:NVDA) on 8/13/2026.
• Sold $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 8/13/2026.
• Sold $1,001 – $15,000 in shares of Lam Research (NASDAQ:LRCX) on 8/13/2026.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 8/12/2026.

Amgen Stock Performance

Amgen stock opened at $461.26 on Wednesday. The firm’s 50 day simple moving average is $420.83 and its 200-day simple moving average is $376.16. The company has a market cap of $249.37 billion, a P/E ratio of 28.67, a price-to-earnings-growth ratio of 3.41 and a beta of 0.43. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen Inc. has a fifty-two week low of $294.48 and a fifty-two week high of $475.64.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The business had revenue of $10.37 billion for the quarter, compared to analyst estimates of $10.07 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm’s revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.64 earnings per share. As a group, equities research analysts predict that Amgen Inc. will post 22.96 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio (DPR) is 62.65%.

Institutional Trading of Amgen

Hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp lifted its position in shares of Amgen by 38.2% in the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after purchasing an additional 11,656,755 shares during the period. Bank of America Corp DE bought a new stake in shares of Amgen in the 2nd quarter valued at $1,831,903,000. Wellington Management Group LLP increased its position in shares of Amgen by 1,102.7% during the second quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock worth $993,031,000 after buying an additional 2,514,254 shares during the period. BlackRock Inc. increased its position in shares of Amgen by 4.8% during the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after buying an additional 2,261,544 shares during the period. Finally, Assenagon Asset Management S.A. increased its position in shares of Amgen by 702.8% during the third quarter. Assenagon Asset Management S.A. now owns 1,535,257 shares of the medical research company’s stock worth $647,126,000 after buying an additional 1,344,010 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, SVP Nancy Grygiel sold 2,970 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,642,098.28. The trade was a 23.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 6,222 shares of company stock valued at $2,540,926 in the last three months. 0.85% of the stock is owned by insiders.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported third-quarter revenue of $10.37 billion, up 8.5% year over year, and adjusted earnings of $6.45 per share. Both figures beat analyst estimates. The company also raised its 2026 revenue and earnings outlook; its revenue midpoint was slightly above consensus. Amgen Raises 2026 Outlook as Q3 Revenue Grows 8% to $10.4 Billion
• Positive Sentiment: Six key growth products reportedly increased sales by 27%, helping offset declining TEPEZZA sales. The company also highlighted pipeline progress, though investors are awaiting further MariTide data. Amgen Q3 2026 Earnings Call Highlights
• Neutral Sentiment: Amgen’s quality chief is retiring and an internal deputy will take over. The transition may draw attention, but the report did not indicate an immediate operational change. Amgen’s quality chief to retire as internal successor steps up
• Negative Sentiment: Despite the earnings beat, investors focused on biosimilar competition facing key products, which weighed on shares after the report. TEPEZZA’s sales decline also highlights pressure within the portfolio. Amgen beats estimates but shares dip on biosimilar concerns
• Negative Sentiment: A recent FDA warning letter over alleged misleading promotion of cancer drug Vectibix adds regulatory risk, though it was not the main focus of the earnings news. Amgen Gets FDA Warning Letter Over Misleading Vectibix Promotion

Wall Street Analyst Weigh In

AMGN has been the topic of several research analyst reports. Morgan Stanley lowered their price objective on shares of Amgen from $362.00 to $359.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 7th. UBS Group increased their target price on Amgen from $430.00 to $470.00 and gave the company a “buy” rating in a report on Friday, October 9th. Canaccord Genuity Group raised their target price on Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded Amgen from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday, October 8th. Finally, Mizuho upped their price target on Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a research report on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus target price of $389.71.

About Senator Whitehouse

Sheldon Whitehouse (Democratic Party) is a member of the U.S. Senate from Rhode Island. He assumed office on January 3, 2007. His current term ends on January 3, 2031.

Whitehouse (Democratic Party) ran for re-election to the U.S. Senate to represent Rhode Island. He won in the general election on November 5, 2024.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.